NEWS
-
Hongmin Chen joins WARF Therapeutics
Chen to head biology for program aiming to produce preclinical candidates CONTACT: Jeanan Yasiri Moe Director of Strategic Communications [email protected] | (608) 960-9892 MADISON, Wis. – WARF Therapeutics, the multimillion-dollar…
-
WARF Therapeutics fall 2021 call for proposals
Program proposal deadline October 8 CONTACT: Jeanan Yasiri Moe Director of Strategic Communications [email protected] | (608) 960-9892 MADISON, Wis. – WARF Therapeutics collaborates with researchers to advance their work closer…
-
WARF Therapeutics spring 2021 call for proposals
Program proposal deadline April 5 CONTACT: Jeanan Yasiri Moe Director of Strategic Communications [email protected] | (608) 960-9892 MADISON, Wis. – WARF Therapeutics collaborates with researchers to advance their work closer…
-
WARF Therapeutics 2020 call for fall proposals
CONTACT: Jacqui Fuller, Strategic Communications and Marketing Manager [email protected] | 608.960.9881 Fall WARF Therapeutics (WT) Program Proposal Deadline: October 15 MADISON, Wis. – WARF Therapeutics encourages researchers working on a…
EVENTS
-
Wed 19April 19 @ 3:30 pm - 6:15 pmWARF Therapeutics Symposium
WARF Therapeutics Symposium
Join WARF Therapeutics, the UW-Madison Department of Chemistry and the UW-Madison Synthesis and Catalysis Center for the 2023 WARF Therapeutics Symposium. 3:30-4:15 p.m. Student Presentations Ben Chi, Weix Group Environmentally…
-
Fri 28April 28 @ 11:30 am - 1:00 pmPhenylketonuria: Insights into Pathophysiology and Novel Therapeutics
Phenylketonuria: Insights into Pathophysiology and Novel Therapeutics
Phenylketonuria (PKU), due to recessively inherited phenylalanine hydroxylase (PAH) deficiency, is among the most common inborn errors of metabolism with an incidence of 1:16,000 live births in the US. PAH…
For business questions, contact John Nagel or Rafael Diaz. If you are a PI interested in submitting your work to the program or talking through next steps, contact Jon Young. You do not need to have a patent; we are interested in talking with you about a new target early in your process.